A study from the Holtzman lab showed that injecting of AD-brain-derived tau extracts into humanized APOE3 Christchurch knock-in mice crossed with the Aβ plaque-depositing APPPS1 model showed reduced NP tau compared to APOE3 expressing mice crossed with APPS1 mice[13]. Here, MAPT is linked to Alzheimer disease.